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Background: A role for autophagy, a conserved cellular response to stress, has recently been demonstrated in
human cancers. Aberrant expression of Beclin-1, an important autophagic gene, has been reported in various
human cancers. In the present study, we investigated the significance and relationship between Beclin-1 expression
and cell proliferation, apoptosis, microvessel density (MVD) and clinical pathological changes or prognosis in human
hepatocellular carcinoma (HCC).
Methods: A total of 103 primary HCC patients were involved in the study. Expression of Beclin-1, PCNA, NET-1,
Bcl-2, Bax, Survivin in cancer cells and CD34 in stromal microvessels were evaluated immunohistochemically in tissue
microarrays comprising 103 cases of HCC and 57 matched adjacent nontumor liver tissues. Correlations between
clinicopathological characteristics and survival of HCC patients were explored.
Results: The positive rate of Beclin-1 was significantly lower in HCC tissues than adjacent tissues (72.8 vs. 89.5%,
χ2 = 6.085, P = 0.015). In HCC, Beclin-1 expression was negatively correlated with cirrhosis background (r = −0.216,
P = 0.029), Edmondson grade (r = −0.249, P = 0.011), vascular invasion (r = −0.246, P = 0.012), PCNA (r = −0.242, P = 0.014),
NET-1 (r = −0.245, P = 0.013), anti-apoptosis protein Bcl-2 (r = −0.245, P = 0.013) and MVD (r = −0.292, P = 0.003), and
positively correlated with pro-apoptosis protein Bax (r = 0.242, P = 0.014).
Significant differences in the 5-year survival rates were seen among patients with Beclin-1 strong positive (++) (59.1%,
13/22), moderate positive (+) (28.3%, 15/53) and weak negative expression (−) (14.6%, 7/28) (P = 0.043). Significant
differences were detected between Beclin-1 (++) and either Beclin-1 (+) (P = 0.036) or Beclin-1 (−) groups (P = 0.008), but
no significant difference between Beclin-1 (+) and Beclin-1 (−) groups (P = 0.281) was observed.
Survival rates were positively related to high Beclin-1 co-expressed with low PCNA, NET-1, or Bcl-2, lower MVD, and high
Bax. Univariate and multivariate Cox regression analysis revealed that Beclin-1 expression was an independent indicator
for overall survival in HCC patients (P < 0.05).
Conclusions: The pathogenesis and progression of HCC are associated with reduced autophagy. The expression of
Beclin-1 and Bax in HCC tissues may provide a synergistic effect towards inhibiting HCC proliferation, infiltration,
metastasis and angiogenesis. Beclin-1 expression may be a valuable prognostic marker of HCC.
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Liver cancer is the sixth most common cancer and the
third leading cause of cancer death worldwide. A total of
749,000 new cases of liver cancer worldwide were esti-
mated in 2008, causing more than 696,000 deaths [1].
Hepatocellular carcinoma (HCC) is the most common
type of liver cancer and one of the most prevalent malig-
nant tumors worldwide [2]. Currently, hepatic resection
is the most common treatment modality for HCC and
one of the most effective interventions for achieving
long-term survival [3,4]. Most HCC patients are diag-
nosed at an advanced stage with underlying liver dys-
function [5], and have very poor prognoses owing to the
low survival. Although several molecular factors and histo-
logical features have been reported to be associated with
the prognosis of HCC [6,7] more effective biomarkers
are necessary to predict the clinical outcome of patients
with HCC.
Autophagy is a genetically programmed process that
enables the recycling of long-lived proteins or damaged
organelles [8,9]. Several studies have demonstrated that
autophagy plays an important role in the development
and progression of cancer [10,11]. However, the role of
autophagy in the growth and metastasis of human carcin-
omas is not completely understood. Therefore, autophagy
has become a critical focus in cancer research [12-14].
Loss of autophagy is likely to contribute to tumor progres-
sion by promoting genome damage and instability. Ap-
proximately 30 specific genes that regulate autophagy
have been identified in yeast, with 16 homologues in hu-
man [15]. Among these genes, Beclin-1 plays a key role
in mammalian autophagy [16]. Beclin-1, the mammalian
counterpart of the yeast Atg6 gene, is part of a type III
phosphatidylinositol 3-kinase complex required for au-
tophagic vesicle formation [17-20]. Abnormal expression
of Beclin-1 has been found in human melanoma [21],
colon [22], ovarian [23] and brain cancers [24]. The aim of
this study was to investigate the expression of Beclin-1 in
HCC tissues, and its relation to clinicopathological fea-
tures and prognostic significance.
Methods
Patients and follow-up
This was a retrospective study based on archived mate-
rials. The study group comprised 103 HCC patients who
were diagnosed with HCC and had undergone curative
resection in Nantong Cancer Hospital and the Affiliated
Hospital of Nantong University between January 2003
and December 2004. The patients were selected accord-
ing to the following criteria: (a) primary HCC, and (b)
previously untreated and with surgery as the first treat-
ment. Therefore, analysis of the data in this series would
reflect actual impact of the tumor biology on the clinical
outcome.All patients had regular follow-up. The follow-up period
was defined as the duration from the date of operation to
the date of either death or the last follow-up. The follow-
up period ranged from 13 to 72 months with a median of
58.4 months. The last follow-up was January 2010. Deaths
from other causes were treated as censored cases. Overall
survival (OS) was evaluated by the duration between the
dates of surgery and death.
Among the 103 patients, 85 were male and 18 were fe-
male, and the ratio of male to female was 4.8:1 (82.5 and
17.5%). The ages of the patients ranged from 21 to 79 years
old with a median of 49 years old. All patients were diag-
nosed and histopathologically confirmed with HCC, and
had complete clinical and pathological records including
medical records, chest roentgenograms, whole body com-
puted tomography films, bone and brain scanning data.
The surgery records were reviewed and the confirmed
pathological diagnosis, tumor size, related hepatitis/liver
cirrhosis, metastasis, and serum alpha fetoprotein (AFP)
values and other relevant data were analyzed. Negative
controls were established from 57 matched adjacent
non-tumor liver tissues that were derived from 113 cases
of HCC.
The study was approved by the Ethics Committee
of the Nantong Cancer Hospital, and all the patients
signed informed consent. To determine factors affecting
survival after operation, conventional variables together
with Beclin-1 expression were determined in the 103
patients.
Tissue microarrays
Tissue microarrays (TMA) were constructed according
to the method of E. Qun (Patent Number: ZL 2008 1
0022 170.4). Briefly, all HCC tissues were stained by
H&E and reviewed by two histopathologists. Representa-
tive areas free from necrotic and hemorrhagic materials
were marked in paraffin blocks. Two cylindrical tissue
cores (1.6 mm diameter) were removed from the donor
blocks and transferred to the recipient paraffin blocks,
and their planar array positions were noted. Three differ-
ent TMA blocks were constructed. Each contained over
100 cylinders and the final TMAs consisted of 103 cases of
HCC and 57 cases of adjacent non-tumor tissues (ANT).
Consecutive sections (4-μm thick) were cut from the array
blocks and placed on adhesion microscope slides for
immunohistochemical staining.
Immunohistochemistry staining
The Envision+/DAB analysis method was performed on
formalin-fixed, paraffin-embedded 5-μm sections from
all patients for the detection of Beclin-1, PCNA, NET-1,
Bcl-2, Bax and Survivin in cancer cells and CD34 in stro-
mal microvessels. Ten consecutive TMA sections were pre-
pared from each TMA block and stained. The paraffin
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retrieval, slides were heated at 95°C for 10 min in so-
dium citrate buffer (10 mM sodium citrate monohydrate,
pH 6.0). The slides were allowed to cool for 20 min at room
temperature and then incubated in Envision + peroxidase
blocking solution (Dakocytomation, Glostrup, Denmark)
for 5 min and rinsed with 0.05% Tris-buffered saline (TBS)/
Tween 20 buffer, pH 7.4. The slides were then incubated
with primary antibodies for 30 min at room temperature.
Anti-Beclin-1 monoclonal antibodies (diluted 1:100) were
obtained from ProSci Inc. Mouse monoclonal antibodies
against human PCNA, NET-1, Bcl-2, Bax, Survivin and
CD34 were purchased from Zymed Laboratories (South
San Francisco, California, USA). The slides were washed
with 0.05% Tween 20 in TBS (pH 7.4). Detection was
achieved with the DAKO Envision+/HRP system (DAKO,
Carpinteria, CA, USA). The color was developed by a
15 min incubation with a diaminobenzidine (DAB) solu-
tion (DAB kit IL1-9032) (Fuzhou Maixin Biotech. Co.,
Ltd., China), and sections were slightly counterstained
with hematoxylin. Positive controls (follicular B cell lymph-
oma tissues with strong nuclear PCNA and cytoplasmic
Bcl-2, hepatocellular carcinoma with cytoplasmic Beclin-1,
NET-1, Bax and Survivin) and negative controls (TBS was
substituted for primary antibody at the same concentra-
tion) were performed for each immunohistochemical run.
Staining patterns and evaluation
Stained sections were evaluated in a blinded manner by
two independent investigators without prior knowledge
of the clinical information using an immunoreactive
score (IRS). Scores were assigned for the intensity and
percentage of positive staining of the cytoplasm/nucleus
in the whole cylinder. Briefly, the IRS assigns subscores
for immunoreactive distribution (0–4) and intensity (0–3),
and multiplies the subscores to yield the IRS score. The
percent positivity was scored as “0” (<5%), “1” (5–25%),
“2” (>25–50%), “3” (>50–75%) or “4” (>75%). The staining
intensity was scored as “0” (no staining), “1” (weakly
stained), “2” (moderately stained) or “3” (heavily stained).
In cases where differences between duplicate tissue cores
were observed, the higher score was considered to be the
final score. The final expression scores of Beclin-1, PCNA,
NET-1, Bcl-2, Bax and Survivin were calculated with the
value of percent positivity score multiplied by staining in-
tensity score, which ranged from 0 to 12. Intratumorally,
the protein expression was defined as follows: negative (−)
(score 0), low expression (+) (score 1–6) and high expres-
sion (++) (score >6).
CD34 was mainly expressed in endothelial cells of micro-
vessels with a scattered pattern of expression. The densest
staining zones were selected at the invading tumor front by
an image-analyzed system. The final microvessel score was
the mean of the vessel counting number obtained fromthese fields. Only blood vessels with a clearly defined lumen
or a linear vessel shape, but not single endothelial cells,
were taken into account. For MVD, a cutoff point of 15
under high power view (×200) was used to define the over-
expression group versus the low expression group.
Statistical analysis
Differences between cancer tissues and adjacent non-tumor
tissues were tested for significance using Wilcoxon signed
rank tests. The Spearman rank correlation test was per-
formed to determine the association of Beclin-1 expression
with either cell proliferation markers (PCNA and NET-1),
apoptosis markers (Bcl-2, Bax and Survivin), MVD, or
clinicopathological characteristics (pathologic classifica-
tion, TNM stage, tumor size). Univariate survival analyses
were used to examine prognostic significance of Beclin-1
expression. Curves for overall survival (OS) were drawn
according to the Kaplan–Meier method and difference
was analyzed by applying the log-rank test for univariate
survival analysis. In accordance with results from Cox
univariate regression analyses, significant factors were
evaluated by multivariate regression analyses to deter-
mine independent prognostic factors. SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA) was used for all statistical
analyses and a P value <0.05 was considered significant.
Results
Beclin-1 expression in HCC and ANT tissues
The expression of Beclin-1 in 103 cases of HCC tissues
and 57 cases of ANT was examined by immunohistochem-
ical analysis (Figure 1, Table 1). A significant difference was
observed in Beclin-1 expression between HCC and ANT
samples (χ2 = 6.085, P = 0.015).
Association of Beclin-1 expression with clinicopathologic
features of HCC
The correlation of Beclin-1 expression with the clinico-
pathologic characteristics of HCC is shown in Table 2.
Intratumoral Beclin-1 expression was negatively corre-
lated with HCC Edmondson grade (Figure 2A–C) (P =
0.011). Beclin-1 expression was stronger in HCC with
Edmondson I–II grade (83.7%, 41/49) than HCC with
III–IV grade (63.0%, 34/54). Similarly, the positive rate
of Beclin-1 expression in HCC with cirrhosis was 69.9%
(58/83) and without cirrhosis was 85.0% (17/20). Beclin-1
expression also negatively correlated with HCC with cir-
rhosis background (P = 0.029) (Figure 3A). The positive
rate of Beclin-1 expression in HCC with vascular invasion
was 32.0% (18/33) and expression in HCC without vas-
cular invasion was 68.0% (57/70). Beclin-1 expression
also negatively correlated with HCC with vascular inva-
sion (P = 0.012) (Figure 3B). There were no significant
associations between Beclin-1 expression and other clini-
copathologic features.
Figure 1 Beclin-1 exhibited cytoplasmic staining in adjacent non-tumor (ANT) tissues (A), bordeling site between HCC and ANT
(B: left, ANT; right: HCC), and HCC (C), respectively. Beclin-1 expression was stronger in ANT than in HCC. Magnification × 400.
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and apoptosis-related proteins and MVD in HCC
Nuclear and cytoplasmic expression of the proliferation-
related proteins PCNA and NET-1, respectively, were de-
tected by immunohistochemical staining in HCC (Figure 4).
The Bcl-2, Bax and Survivin apoptosis-related proteins
showed cytoplasmic staining (Figure 5). CD34 expression
in stromal microvessels exhibited a scattered pattern
(Figure 6). In the 103 HCC cases, the average MVD was
198 ± 96/0.64 mm2. The cases were divided into three
grades: higher MVD (34 cases) with an average of 308 ± 46/
0.64 mm2, middle MVD (35 cases) at 194 ± 23/0.64 mm2
and lower MVD (34 cases) at 91 ± 37/0.64 mm2.
As seen in Table 3, Spearman related analysis shows
the association between the expression of Beclin-1 and
proliferation and apoptosis related proteins and MVD in
the 103 HCC cases. Significant negative correlations be-
tween the expression of Beclin-1 and PCNA (r = −0.245,
P = 0.013), Beclin-1 and NET-1 (r = −0.382. P < 0.001),
Beclin-1 and Bcl-2 (r = −0.226, P = 0.021), and Beclin-1 and
MVD (r = −0.292, P = 0.003) were observed. Conversely, a
significant positive relationship between the expression of
Beclin-1 and Bax (r = 0.242, P = 0.014) was identified. How-
ever, no significant relationship between the expression
of Beclin-1 and Survivin (r = 0.044, P = 0.659) was seen.
Furthermore, Pearson related analysis demonstrated that
Beclin-1 was negatively related to PCNA (r =−0.426, P <
0.001), NET-1 (r = −0.382, P < 0.001), and MVD (r = −0.207,
P < 0.01), whereas it was positively related to Bax (r = 0.358,
P < 0.001) (Figure 7). Although Beclin-1 was negatively re-
lated to Bcl-2 according to Spearman related analysis, noTable 1 Beclin-1 expression in HCC and ANT tissues
Sample Cases Beclin-1 expression χ2/P
(−) % (+) % (++) %
HCC 103 28 27.4 53 51.4 22 21.4 χ2=6.085
ANT 57 6 10.5 31 54.4 20 35.1 p=0.015significant relationship between the two was identified by
Pearson related analysis (P > 0.05).
The association of Beclin-1 expression with survival
analysis of HCC
The association between Beclin-1 expression and patient
survival was investigated using Kaplan-Meier analysis
and Log-rank test with single-factor and multivariate
analysis for the follow-up data from the 103 HCC cases.
The median overall survival (OS) after operation for the
103 patients was 41 months (ranging from 1 to 91 months).
Kaplan-Meier analysis of patient survival revealed that low
expression of Beclin-1 may point to a poor prognosis for
HCC patients. The median OS of the Beclin-1 (++), (+)
and (−) groups was 62, 36 and 28.5 months, respectively,
with the log-rank test demonstrating significant difference
(P = 0.013, Figure 8). The prognosis of the Beclin-1 (++)
group was better than that of the (+) group (P = 0.036) and
the (−) group (P = 0.008), although no significant difference
in OS was observed between Beclin-1 (+) and (−) groups
(P = 0.281).
The associations between Beclin-1 with either PCNA,
NET-1, Bcl-2, Bax expressions or CD34 positive MVD
as well as patient survival were investigated. All cases
were further divided into the following groups according
to co-expression of Beclin-1 and each of the four genes
and MVD. Because no significant difference in OS was
observed between the Beclin-1 (+) group and (−) group,
both groups were evaluated together as a low expression
group. The other four genes (PCNA, NET-1, Bcl-2 and
Bax) and MVD groups, both the middle and lower groups,
were also treated the same by combining them into a low
expression group and low MVD group (+); whereas
the (++) group was an overexpression group and higher
MVD group (++). The 5-year OS of cases with positive co-
expression of both genes were investigated using Kaplan-
Meier analysis (Figure 9) and Log-rank test (Table 4). The
results indicated that the survival rates were significantly
Table 2 Correlation between Beclin-1 expression and clinicopathologic characteristics in HCC
Characteristics N Beclin-1 expression R (X2# )/P
(−) % (+) % (++) %
Age 1.382#/0.155
<50 y 53 12 22.6 28 52.8 13 24.5
≥50 y 50 16 32 25 50 9 18
Sex 4.360#/0.175
Male 85 23 27.1 47 55.3 15 17.6
Female 18 5 27.8 6 33.3 7 38.9
AFP −0.096/0.334
<50 ng/ml 39 8 20.5 22 56.4 9 23.1
≥50 ng/ml 64 20 31.3 31 48.4 13 20.3
HbsAg −0.111/0.264
Negative 20 4 20 10 50 6 30
Positive 83 24 28.9 43 51.8 16 19.3
Liver cirrhosis 0.216 /0.029*
No 20 3 15 9 45 8 40
Yes 83 25 30.1 44 53 14 16.9
Tumor size −0.035/0.726
≤2 cm 14 3 21.4 7 50.0 4 28.6
2 cm-10 cm 78 22 28.2 41 52.6 15 19.2
>10 cm 11 3 27.3 5 45.5 3 27.3
Edmondson grades −0.249/0.011*
I-II 49 8 16.3 27 55.1 14 28.6
III-IV 54 20 37 26 48.1 8 14.8
TNM stage 0.146/0.142
I 10 2 10 4 40 4 50
II 41 7 17.1 27 71.1 7 18.4
III 36 13 30.7 16 46.2 7 23.1
IV 16 6 25 6 37.5 4 37.5
Capsule integrity −0.054/0.588
Yes 67 16 23.9 34 50.7 17 25.4
No 36 12 33.3 19 52.8 5 13.9
Vascular invasion −0.246/0.012*
No 70 13 18.6 40 57.1 17 24.3
Yes 33 15 45.5 13 39.4 5 15.2
Tumor number −0.158/0.111
Single 73 17 23.6 38 52.05 18 25
Multiple 30 11 37.9 15 50.0 4 13.8
*, p<0.05.
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Beclin-1 and NET-1 expression (P = 0.000), Beclin-1 and
Bcl-2 expression (P = 0.001), Beclin-1 and Bax expression
(P = 0.003), and Beclin-1 and MDV (P = 0.003). The 5-year
OS of cases with co-expression of Beclin-1 (++)/PCNA (+)
was significantly higher than that in cases with Beclin-1
(+)/PCNA (+) and Beclin-1 (+)/PCNA (++) (65.0 vs. 30.2%and 16.7%, respectively; P < 0.01). Cases with Beclin-1
(++)/NET-1 (+) showed a significantly higher 5-year OS
than cases with Beclin-1 (+)/NET-1 (+) (64.7 vs. 36.7%,
respectively; P = 0.046); the 5-year OS of cases with
Beclin-1 (++)/Bcl-2(+) was significantly higher than that
of cases with Beclin-1 (+)/Bcl-2 (++) and Beclin-1 (+)/Bcl-2
(+) (61.90 vs. 10% and 29.6%, respectively; P < 0.01), and
Figure 2 Beclin-1 expression in well-differentiated HCC with Edmondson I (A); moderately differentiated HCC with Edmondson II grade
(B); and poorly differentiated HCC with III–IV grade (C). Beclin-1 was expressed in the cytoplasm of HCC cells, and with the increased grade
of HCC, Beclin-1 expression was lower. Magnification × 400.
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(+)/Bax (++) were significantly higher than cases with
Beclin-1 (+)/Bax (+) (47.1 and 70.0% vs. 21.1%, respect-
ively; P < 0.01). The cases with Beclin-1 (++)/MVD-middle
showed significantly higher 5-year OS than cases with
Beclin-1 (+)/MVD-high (57.1 vs. 21.2%, respectively; P <
0.01) and Beclin-1(+)/MVD-middle (57.1 vs. 31.3%, res-
pectively; P < 0.05). In addition, 5-year OS of cases with
Beclin-1 (+)/Bcl-2 (+) was significantly higher than cases
with Beclin-1 (+)/Bcl-2 (++) (29.6 vs. 10%, respectively; P =
0.015), and 5-year OS in cases with Beclin-1 (+)/NET-1 (+)
was significantly higher than that in cases with Beclin-1 (+)
NET-1 (++) (36.7 vs. 12.5%, P < 0.001). The 5 year OS
was 100%, 100% and 0% in cases with Beclin-1 (++)/Bax
(++) (5/5), Beclin-1 (++)/MVD-high (1/1) and Beclin-1
(++)/PCNA (++) (0/2). No other significant statistical dif-
ferences among the other groups were found (P > 0.05).
Cox regression analysis was used to compare Beclin-1
expression with clinicopathological features of survival
prediction (Table 5). As shown in Table 5, using univariate
Cox regression analysis, the parameters such as tumor size
(>5 cm), Edmondson grades (III + IV), TNM stage (III +Figure 3 Beclin-1 expression in HCC with liver cirrhosis (A) and vascu
low expression level. Magnification × 200.IV), vascular invasion and capsular infiltration and Beclin-1
expression (− and +) were significantly associated with poor
OS. By multivariate Cox regression analysis, only large
tumor size, higher Edmondson grades, late stage and loss of
or lower expression of Beclin-1 were identified to be
independent prognostic factors for OS (P < 0.05). Together
this showed that Beclin-1 together with tumor size, tumor
differentiation, and TNM stages were strongly associated
with OS. However, other variables including age, sex, cir-
rhosis background, capsular infiltration, serum AFP level,
HBsAg status and multinodular tumor seemed to show a
general trend, with subtle differences in survival without
significance.
Discussion
Autophagy is a tightly-regulated catabolic process that
involves the degradation of intracellular components via
lysosomes during cell growth, development and tumori-
genesis [25]. The role that autophagy plays in oncogenesis
is double sided and dependent on context. In a tumor
microenvironment, autophagy can serve as a means of tem-
porary survival in response to metabolic stress. However, aslar invasion (B). Low positive signal of Beclin-1 staining indicated its
Figure 4 The expression of PCNA (A) and NET-1 (B) in HCC. PCNA strong positive staining was seen in the nucleus and NET-1 was detected
in the cytoplasm. Magnification × 400.
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sive autophagy, cell death would follow. Moreover, emer-
ging evidence has revealed autophagic features in cells
treated with chemotherapeutic agents. Whether the high
level of autophagy induced by cytotoxic drugs should be
regarded as a direct cell death execution pathway or a gar-
bage disposal mechanism whereby cells preserve their via-
bility for long-time survival is still not clear [26]. Currently,
numerous studies have examined the molecular mechanism
of autophagy to elucidate the role that autophagy plays in
cancer initiation and progression. Beclin-1, the mammalian
ortholog of Atg6, is required for a proximal step in autoph-
agy [27], recruiting proteins from the cytoplasm for autoph-
agic degradation or in supplying the autophagic pathway
with membrane components [18]. Zou M et al. found that
Oroxylin A, a natural mono-flavonoid extracted from
Scutellariae radix, induced Beclin-1-mediated autophagy
in human HCC HepG2 cells [28]. Inactivation of Beclin-1
has been demonstrated to result in increased tumorigen-
esis in mice. Beclin-1 is monoallelically deleted in a high
percentage of human breast, ovarian and prostate cancers,
and decreased levels of the protein have been found in
human breast, ovarian and brain tumors [24,29-31].Figure 5 The expression of Bcl-2 (A), Bax (B) and Survivin (C) in HCC.Moreover, enforced expression of Beclin-1 has been shown
to inhibit the formation of human breast tumors in mouse
models [24,32]. Therefore, Beclin-1 could play a role as a
tumor suppressor and its decreased expression may con-
tribute to the development of human cancer.
In our study, Beclin-1 was mainly located in the cyto-
plasm of HCC tissues, along with a significantly decreased
level of expression in HCC tissues compared with the adja-
cent nontumor tissues. These results are similar to those by
Liang et al., in which lower expression of Beclin-1 was
found in human breast epithelial carcinoma cell lines and
tissues, and high levels of Beclin-1 expression was expressed
ubiquitously in normal breast epithelial as detected by west-
ern blot and immunohistochemistry [30]. Another study
showed that transfection of Beclin-1 into a transformed
breast carcinoma cell line decreased its tumorigenic poten-
tial in nude mice [27]. These findings suggested that these
carcinomas might possess defective autophagy. Other find-
ings revealed that autophagy enhanced tumor development
and protected tumor cells from stimuli that result in cell
death [11,33]. Ahn et al. reported that the increased Beclin-
1 expression in colorectal and gastric cancer cells compared
with normal epithelial cells suggests that neo-expressionAll three were expressed in the cytoplasm. Magnification × 400.
Figure 6 CD34 expression with lower (A), middle (B) and higher (C) MVD in HCC. Magnification × 200.
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tumorigenesis [34]. In in vivo HCC xenograft tumors, in-
duced autophagy led to inhibition of tumor growth [28],
which supports an autophagy-mediated antitumor activity.
These divergent results also suggest that Beclin-1 may
function in a tissue-specific manner.Table 3 The correlation of the expression of Beclin-1 with either
Related proteins N Bec
(—) % (+
PCNA
- 21 4 19.0 8
+ 62 16 25.8 35
++ 20 8 40.0 10
NET-1
- 7 0 0.0 2
+ 59 15 25.4 32
++ 37 13 35.1 19
Bcl-2
- 73 16 21.9 38
+ 19 7 36.8 10
++ 11 5 45.5 5
Bax
- 51 21 41.2 21
+ 27 5 18.5 14
++ 15 2 13.3 8
Suvivinin
- 39 12 30.8 20
+ 43 10 23.3 22
++ 21 6 28.6 11
MVD
Higher 34 11 32.4 22
Middle 35 15 42.9 8
Lower 34 2 5.9 23
*p<0.05.In this study, expression level of Beclin-1 was negatively
correlated with HCC Edmondson grades, HCC with cir-
rhosis background and vascular invasion. We found that
Beclin-1 expression was higher in HCC with Edmondson
I–II grade than that with III–IV grade. Similarly, Beclin-1
expression was significantly lower in HCC with vascularproliferation and apoptosis related proteins or MVD in HCC
lin-1 expression r/P

























Figure 7 The relationship between Beclin-1 and PCNA (A), NET-1 (B), Bax (C) and MVD (D) by Pearson related analysis. The scatter plot
graph showed that Beclin-1 was negatively related to PCNA, NET-1, and MVD, and positively related to Bax.
Figure 8 Kaplan-Meier survival curves stratified for Beclin-1
expression in whole study population. The median OS of Beclin-1
(++) group was much higher than the other two groups.
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cular invasion and cirrhosis. These results indicate that
Beclin-1 may be an immediate-early response gene in
tumorigenesis. The absence of Beclin-1 could be an early
event in the process of HCC, and thus play a more critical
role in HCC progression.
To examine the underlying mechanisms of how Beclin-1
affects HCC malignant transformation, the association of
Beclin-1 expression in HCC with cellular proliferation-
related proteins such as PCNA and NET-1, and apoptosis-
related proteins including Bcl-2, Bax and Survivin were
studied. PCNA antigen is a nuclear antigen expressed in
proliferating cells in all stages of the cell cycle except stage
G0 and serves as a marker for proliferation. NET-1, a
member of the transmembrane 4 superfamily (TM4SF),
acts as a molecular service protein that enhances the
formation and stability of functional signal transduction
Figure 9 Kaplan-Meier survival curves of HCC patients with Beclin-1 and PCNA co-expression (A), Beclin-1 and NET-1 co-expression (B),
Beclin-1 and Bcl-2 co-expression (C), Beclin-1 and Bax co-expression (D), and Beclin-1 and MVD co-expression (E) (log-rank
test, P < 0.05).
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http://www.biomedcentral.com/1471-2407/14/327complexes by connecting specific cell surface proteins,
such as lineage specific proteins, integration proteins
and other TM4SFs members. NET-1 thus plays an import-
ant role in cell signal transduction, regulation, adhesion,
migration, proliferation and differentiation [5,6]. Previous
studies have shown that NET-1 expression was related
closely to HCC proliferation, with significant upregulation
during formation of cancers [14]. Bcl-2 is one of the mainanti-apoptotic proteins normally residing in the mitochon-
drial membrane and cytoplasm. When cells are deprived of
survival signals or subjected to stress, Bcl-2 is released
from the mitochondrial membrane and replaced by pro-
apoptotic factors, such as Bax. When Bcl-2 levels decrease,
the permeability of the mitochondrial membrane increases,
and several proteins that can activate the caspase cascade
are released. In this present study, Spearman related
Table 4 The 5-year overall survival rate of patients with both genes co-expression
Groups Gene expression Cases Survival 5-year OS (%) Compared Rank test
a Beclin-1++/PCNA++ 2 0 0
b Beclin-1++/PCNA+ 20 13 65.0 b vs. c P=0.008
c Beclin-1+/PCNA++ 18 3 16.7 b vs. d P=0.025
d Beclin-1+/PCNA+ 63 19 30.2 C vs. d P>0.05
e Beclin-1++/NET-1++ 5 2 40.0 E vs. f P>0.05
f Beclin-1++/NET-1+ 17 11 64.7 f vs g P=0.000
g Beclin-1+/NET-1++ 32 4 12.5 h vs g P=0.003
h Beclin-1+/NET-1+ 49 18 36.7 f vs h P=0.046
i Beclin-1++/Bcl-2++ 1 0 0
j Beclin-1++/Bcl-2+ 21 13 61.9 J vs k P=0.000
k Beclin-1+/Bcl-2++ 10 1 10.0 J vs l P=0.029
l Beclin-1+/Bcl-2+ 71 21 29.6 l vs k P=0.015
m Beclin-1++/Bax++ 5 5 100.0
n Beclin-1++/Bax+ 17 8 47.1 n vs. o P>0.05
o Beclin-1+/Bax++ 10 7 70.0 n vs. p P>0.05
p Beclin-1+/Bax+ 71 15 21.1 o vs. p P=0.010
q Beclin-1++/MVD++ 1 1 100.0
r Beclin-1++/MVD+ 21 12 57.1 r vs. s P=0.000
s Beclin-1+/ MVD++ 33 3 21.2 r vs. t P=0.043
t Beclin-1+/ MVD+ 48 15 31.3 s vs. t P>0.05
+, including – and +.
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http://www.biomedcentral.com/1471-2407/14/327analysis showed a significant negative relationship between
Beclin-1 and PCNA, between Beclin-1 and NET-1, and be-
tween Beclin-1 and Bcl-2. A significant positive relation-
ship was observed between Beclin-1 and Bax. However, no
significant relationship was observed between Beclin-1
and Survinin. Pearson related analysis demonstrated thatTable 5 Univariate and multivariate Cox regression analysis f
clinicopathological variables
Variables Univariate ana
Hazard ratio (95% CI)
Age 0.814 (0.500-1.325)
Sex 1.139 (0.621-2.091)
Tumor size ( ≤ 5 cm vs. >5 cm) 2.408 (1.474-3.935)
Edmondson grades (I+II vs. III+IV) 1.421 (1.109-1.821)
TNM stage (I+II vs. III+IV) 1.566 (1.217-2.014)
Capsular infiltration (Negative vs. Positive) 0.555 (0.340-0.906)
Vascular invasion (Negative vs. Positive) 1.911 (1.162-3.143)
Cirrhosis background 1.586 (0.809-3.110)
Serum AFP level 1.606 (0.961-2.683)
HbsAg status 1.317 (0.689-2.516)
Multinodular tumor (Single vs. Multiple) 0.998 (0.521-1.909)
Beclin-1 [(−+) vs. (++)] 0.690 (0.492-0.967)Beclin-1 was negatively related to PCNA and NET-1, and
positively related to Bax, but no significant relationship
was detected between Beclin-1 and Bcl-2, which might be
owed to the fact that the number of Bcl-2 positive cases
was too low to be representative in the total cases. Bcl-2 is
an interacting partner of Beclin-1 and negatively regulatesor overall survival based on Beclin-1 expression and
lysis Multivariate analysis
P Adjusted hazard ratio (95% CI) P
0.407
0.673
0.000 2.532 (1.539-4.165) 0.000
0.005 1.365 (1.062-1.753) 0.015







0.031 0.667 (0.473-0.941) 0.021
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http://www.biomedcentral.com/1471-2407/14/327its autophagy function [35]. In the present work, we did
not assay the expression of autophagy markers such as
LC3 or p62/SQSTSM1 [36]. With relevance to our find-
ings, a previous study showed that high expression of
Beclin-1 correlated with a good prognosis in non-Hodgkin
lymphoma when the tumors were Bcl-2 low or negative
expressing and positive for the autophagy marker LC3
[36]. Because Bax is a pro-apoptosis factor and Bcl-2 is an
apoptosis inhibitor, our data identifying an association of
Beclin-1 expression with Bax overexpression suggests that
cellular autophagy may be positively related to apoptosis
in HCC. Similarly, Zou M et al. also observed that autoph-
agy occurred prior to noticeable apoptosis in HepG2 cells.
We propose a novel function for autophagy in promoting
death of HCC cells, which involves inhibiting cell prolifer-
ation and promoting cell apoptosis. However, the mecha-
nisms underlying this novel function remain unclear.
Angiogenesis plays an important role in the malignant
transformation, growth, and metastasis of parenchymal
tumors. Tumor angiogenesis is regulated by angiogenesis
factors generated and excreted by tumor cells. HCC is a
highly vascularized tumor that requires the formation of
numerous blood vessels to receive sufficient blood sup-
ply to grow and proliferate. Consequently, angiogenesis
is a crucial process in the development of HCC. In our
HCC group, Spearman related analysis and Pearson re-
lated analysis demonstrated that Beclin-1 expression nega-
tively correlated to MVD.
Cellular proliferation, apoptosis and angiogenesis are
important in cancer occurrence, development and progres-
sion processes. As tumor associated factors, the expressions
of PCNA and NET-1 are closely related to cell proliferation.
The elevated expression of Bax and decreased expres-
sion of Bcl-2 leads cells to activate apoptosis to higher
levels. Increasing Beclin-1 expression in HCC cells was
always accompanied by lower MVD. Therefore, we hy-
pothesized that the co-expression of these genes in HCC
has a synergistic effect through inhibiting proliferation
and promoting both apoptosis and angiogenesis, which
greatly reduces the malignant progression of cancers. The
prognostic significance of Beclin-1 has been studied in
several types of solid tumors, and decreased expression of
Beclin-1 was correlated with tumor progression in breast,
ovarian and brain cancers [21-24]. In our study, Kaplan-
Meier analysis showed that the patients with higher
expression of Beclin-1 had longer OS, suggesting that
Beclin-1 expression could indicate prognosis of HCC.
Our findings are consistent with those previously observed,
showing that decreased Beclin-1 expression was correlated
with a lower survival rate in patients with esophageal can-
cer, glioblastoma and colon cancers [22,24,37], and with
the observation that high expression of Beclin-1 correlates
with a better survival rate in non-Hodgkin lymphoma
patients [36].Several authors have reported the expression and signifi-
cance of these genes (Beclin-1, PCNA, NET-1 and Bcl-2)
in HCC [8,16,17], but until now, no study has examined
the correlations among expression of these genes in HCC
and the relationship between co-expression of these genes
and survival of HCC patients. This study focused on sig-
nificance of the co-expression of related genes in HCC
prognosis. In the present study, co-expression patterns
such as low Beclin-1 with high PCNA expression, low
Beclin-1 with high NET-1 expression, and low Beclin-1
with high Bcl-2 expression were associated with an in-
creased risk of HCC progression. The co-expression was
also associated with malignant progression and poor prog-
nosis of patients. In addition, the 5-year OS of patients
with co-expression of higher Beclin-1 expression with
the lower expression of PCNA, NET-1, Bcl-2 or lower
MVD was significantly higher than other expression pat-
terns. This is the first report showing that co-expression
of Beclin-1 and PCNA, NET-1, Bcl-2, or Bax, or MVD is
associated with HCC patient prognosis. The observa-
tions also indirectly support the concept that synergistic
effects of Beclin-1 and Bax may contribute to better
prognosis by simultaneously promoting autophagy and
apoptosis in HCC.
Some of the clinicopathological factors and the expres-
sion of Beclin-1 selected by univariate Cox regression
analysis showed significant difference in HCC survival.
Tumor size (>5 cm), Edmondson grades (III + IV), TNM
stage (III + IV), vascular invasion, capsular infiltration and
low expression of Beclin-1 (− and +) were significantly as-
sociated with poor OS. In addition, multivariate Cox regres-
sion analysis showed that only large tumor size (>5 cm),
higher Edmondson grades (III + IV), late stage (TNM stage
III + IV) and loss or lower expression of Beclin-1 were inde-
pendent prognostic factors for OS Beclin-1, together with
tumor size, tumor differentiation, and TNM stages, were
strongly associated with OS. The mechanisms underlying
the involvement of these factors in HCC need further
investigation.Conclusion
Our study shows that the expression of the autophagic
gene Beclin-1 and its autophagic activities are suppressed
in some HCC tissues. Autophagy defects may be associ-
ated with tumor progression and poor prognosis of HCC.
The expression of Beclin 1 may be a valuable marker to
estimate HCC progression. However, further studies are
required to confirm these findings and to provide better
understanding of the autophagy mechanism in the devel-
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